Cargando…
Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy
Migraine is a common neurological disorder that is present in a large proportion of the global population. It is estimated to occur in around 20.7% of women and 10.7% of men in the United States. The pathophysiology of migraine is a major focus of research, and medications have been developed to int...
Autores principales: | Anderson, Christopher C, VanderPluym, Juliana H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327670/ https://www.ncbi.nlm.nih.gov/pubmed/37426628 http://dx.doi.org/10.2147/DDDT.S380440 |
Ejemplares similares
-
Fremanezumab in the treatment of migraines: evidence to date
por: Robblee, Jennifer, et al.
Publicado: (2019) -
Ubrogepant in the Acute Management of Migraine: A Narrative Review
por: Chiang, Chia-Chun, et al.
Publicado: (2021) -
The potential of lasmiditan in migraine
por: Mecklenburg, Jasper, et al.
Publicado: (2020) -
Efficacy of lasmiditan for the acute treatment of perimenstrual migraine
por: MacGregor, E Anne, et al.
Publicado: (2022) -
Fremanezumab for preventive treatment of migraine: Functional status on headache-free days
por: VanderPluym, Juliana, et al.
Publicado: (2018)